[Feasibility of immunotherapy administration to patients with bronchial cancer in a Hospital-at-Home setting]

Bull Cancer. 2021 Apr;108(4):437-439. doi: 10.1016/j.bulcan.2020.11.017. Epub 2021 Mar 4.

[Article in French]

Authors

Aldo Renault¹, Maï Fradin², Mathieu Frouvelle³, Alice Seris⁴, Nicolas Kiffer²

Affiliations

¹ Centre Hospitalier de Pau, service de pneumologie, 4, boulevard Hauterive, 64000 Pau.
² Centre Hospitalier de Pau, service d'hospitalisation à domicile, 4, boulevard Hauterive, 64000 Pau.
³ Centre Hospitalier de Pau, unité de recherche clinique, 4, boulevard Hauterive, 64000 Pau.
⁴ Centre Hospitalier de Pau, unité de recherche clinique, 4, boulevard Hauterive, 64000 Pau. Electronic address: alice.seris@ch-pau.fr.

PMID: 33676724
DOI: 10.1016/j.bulcan.2020.11.017

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use*
Bronchial Neoplasms / drug therapy*
Drug Approval
Feasibility Studies
Home Care Services, Hospital-Based*
Humans
Immune Checkpoint Inhibitors / therapeutic use
Nivolumab / therapeutic use
Patient Satisfaction

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
durvalumab
Nivolumab
atezolizumab
pembrolizumab